Skip to main content

Advertisement

Table 3 Comparison of clinicopathologic characteristics among the subgroups

From: Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

Variable Subgroup 1
(n = 141)
Subgroup 2
(n = 51)
Subgroup 3
(n = 99)
Subgroup 4
(n = 154)
P 1 P 2 P 3 P 4
Age (years) 0.290a 0.042a 0.108a 0.526a
 Mean ± SDb 48.4 ± 10.6 46.6 ± 9.6 50.7 ± 11.9 47.6 ± 11.7
 <50 78 33 41 87
 ≥50 63 18 58 67
Gender 0.216 0.527 0.988 0.092
 Males 124 48 87 131
 Females 17 3 12 23
HBeAg 0.011 <0.001 0.441 0.360
 Positive 42 6 25 10
 Negative 99 45 74 144
Tumor size (cm) 0.233a 0.922a 0.158a 0.020a
 Mean ± SDb 4.8 ± 3.1 4.2 ± 2.8 5.4 ± 3.1 5.5 ± 3.3
 <5 86 36 45 76
 ≥5 55 15 54 78
Tumor number 0.460 0.194 0.278 0.360
 Single 131 45 88 144
 Multiple 10 6 11 10
Pathologic grade 0.561 0.375 0.498 0.444
 I 10 2 12 9
 II 85 36 56 94
 III 45 13 30 50
 IV 1 0 1 1
Microvascular thrombus 0.756 0.210 0.430 0.273
 Yes 19 6 10 9
 No 122 45 89 145
Tumor capsule (cases) 0.083 0.729 0.056 0.648
 Complete 64 23 43 69
 Incomplete 49 11 24 42
 Without 28 17 32 43
Liver cirrhosis 0.017 0.738 0.852 0.012
 Yes 101 45 72 109
 No 40 6 27 45
AFP (ng/mL) 0.216 0.514 0.897 0.523
 ≤25 61 17 42 59
 >25 80 34 57 95
ALT (IU/L) 0.052a <0.001a 0.485a 0.220a
 Mean ± SDb 52.4 ± 29.3 42.8 ± 32.1 49.8 ± 26.0 36.8 ± 22.3
 ≤40 53 30 46 104
 >40 88 21 53 50
AST (IU/L) 0.009a 0.008a 0.508a 0.596a
 Mean ± SDb 44.4 ± 27.1 33.7 ± 16.8 42.4 ± 17.6 35.5 ± 21.6
 ≤45 96 42 62 127
 >45 45 9 37 27
ALB (g/L) 0.028a 0.092a 0.372a 0.168a
 Mean ± SDb 42.8 ± 3.5 44.1 ± 3.7 42.3 ± 4.0 43.2 ± 3.9
 <35 2 1 95 150
 ≥35 139 50 4 4
TBIL (μmol/L) 0.931a 0.878a 0.114a 0.193a
 Mean ± SDb 16.0 ± 7.8 15.9 ± 5.8 14.5 ± 5.4 14.6 ± 5.8
 ≤20.5 116 40 84 133
 >20.5 25 11 15 21
Prothrombin time (s) 0.929a 0.182a 0.824a 0.345a
 Mean ± SDb 12.7 ± 1.5 12.7 ± 1.6 12.6 ± 1.3 12.4 ± 1.2
 ≤13.5 101 38 76 131
 >13.5 40 13 23 23
Recurrence 0.535 0.001 0.180 0.312
 Yes 79 26 64 66
 No 62 25 35 88
Death 0.189 0.001 0.731 0.276
 Yes 41 10 48 42
 No 100 41 51 112
  1. Definition of the four subgroups: (1) subgroup 1, antiviral therapy and baseline HBV DNA ≥ 2000 IU/mL (n = 141); (2) subgroup 2, antiviral therapy and baseline HBV DNA <2000 IU/mL or undetectable (n = 51); (3) subgroup 3, non-antiviral therapy and baseline HBV DNA ≥2000 IU/mL (n = 99); and (4) subgroup 4, non-antiviral therapy and baseline HBV DNA <2000 IU/mL or undetectable (n = 154)
  2. P 1 P value calculated by comparing subgroup 1 and subgroup 2, P 2 P value calculated by comparing subgroup 3 and subgroup 4, P 3 P value calculated by comparing subgroup 1 and subgroup 3, P 4 P value calculated by comparing subgroup 2 and subgroup 4, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB serum albumin, TBIL serum total bilirubin
  3. a t test used
  4. b Except for these values, other values are presented as the number of patients and were compared by the χ2 test